The global focus on gene and cell therapies has grown exponentially in recent years as more development programs have advanced to later stages or even approval. In this article published in Life Science Leader, the authors discuss the challenges for gene and cell therapy research and how new approaches to innovation and financing, such as platform diversification and partnering with academia, could help support development of cell and gene therapies. To access the article, click here.
The authors wish to acknowledge the contributions of Pascale Diesel, Stephanie Donahue, and Michael Krepps to this article.
Disparities in screening and diagnosis for triple negative breast cancer
Gilead Sciences asked Charles River Associates and Tigerlily Foundation to examine the extent to which policies associated with triple negative breast cancer...